Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Capsida
company
About
Capsida is a biotechnology company that specializes in tackling monogenetic and sporadic CNS and non-CNS disorders.
- 51 - 100
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $50M
- Industries
- Biotechnology,Genetics,Health Care
- Founded date
- Jan 1, 2019
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Capsida is a biotechnology company that specializes in tackling monogenetic and sporadic CNS and non-CNS disorders. It features a proprietary adeno-associated virus (AAV) engineering platform that generates capsids optimized to target specific tissues and cells in the diseased organ.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$50M
Capsida has raised a total of
$50M
in funding over 2 rounds. Their latest funding was raised on
Apr 29, 2021 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 29, 2021 | Series A | $50M | 1 |
Versant Ventures
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Capsida is funded by 1 investors.
Versant Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Versant Ventures
|
Yes | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
